01218nam2 22002893i 450 PUV026341220231121125611.020190116d1938 ||||0itac50 bafrefrz01i xxxe z01n˜2: œEtudes sur la monarchie AttalideMaurice HolleauxParisE. de Boccard1938198 p., 2 c. di tav.ill.26 cm.001SBL00066302001 Etudes d'épigraphie et d'histoire grecquesMaurice Holleaux2935.06Storia del mondo antico. Mesopotamia e altopiano iranico. Periodi ellenistico, seleucide, partico, 332 a.C.-226.22938.08Storia dell'antica Grecia. Periodo ellenistico, 323-146 a.C.22Holleaux, MauriceTO0V050518070194671ITIT-0120190116IT-FR0017 Biblioteca umanistica Giorgio ApreaFR0017 NPUV0263412Biblioteca umanistica Giorgio Aprea 52DLM L /B /124.2 52DUP0009019275 VMB RS A 2019011620190116 52Etudes sur la monarchie Attalide3613390UNICAS03503nam 2200637Ia 450 991078459850332120200520144314.01-281-11983-097866111198360-08-054824-5(CKB)1000000000357843(EBL)305505(OCoLC)162131368(SSID)ssj0000098016(PQKBManifestationID)11543273(PQKBTitleCode)TC0000098016(PQKBWorkID)10121606(PQKB)10688063(Au-PeEL)EBL305505(CaPaEBR)ebr10188620(CaONFJC)MIL111983(MiAaPQ)EBC305505(EXLCZ)99100000000035784319930716d2007 uy 0engur|n|---|||||txtccrAdvances in antiviral drug designVolume 5[electronic resource] /editor, E. De ClercqGreenwich, CT ;London, England Jai Press20071 online resource (265 p.)Advances in antiviral drug design ;5Description based upon print version of record.0-444-52173-9 Includes bibliographical references and index.I. IntroductionII. Design; III. Synthesis; IV. Antiviral activity; Acknowledgements; References; Chapter 4. Synthesis and antiviral evaluation of broad spectrum, orally active analogs of cidofovir and other acyclic nucleoside phosphonates; I. Introduction; II. Synthesis of hexadecyloxypropyl and related esters of cidofovir; III. Antiviral evaluation and spectrum of activity; IV. Structure activity relationships; V. Cellular metabolism; VI. Oral pharmacokinetics and tissue distribution; VII. Antiviral activity in animal models of viral diseasesVIII. Alkoxyalkyl esters of (S)-HPMPA and other acyclic nucleoside phosphonatesIX. Conclusions; Acknowledgements; References; Chapter 5. CCR5 antagonistsCCR5 antagonists for the treatment ofHIV infection and AIDS; I. Introduction; II. Inhibition of HIV entry; III. CCR5 as a drug target; IV. The discovery of novel CCR5 antagonists; V. Molecular mechanisms; VI. Resistance to CCR5 antagonists in vitro and in the clinic; VII. Conclusions; References; Chapter 6. The medicinal chemistry of the DATADATA and DAPYDAPY series of HIV-1HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIsNNRTIs)AbstractI. Introduction; II. The diaryltriazine (DATA) series; III. The diarylpyrimidine (DAPY) series; IV. Conclusion; Acknowledgements; References; IndexRegularly reviewing the ""state-of-the-art"" developments in the antiviral drug research field, this latest volume spans the conceptual design and chemical synthesis of new antiviral compounds. It discusses their structure-activity relationship, mechanism and targets of action, pharmacological behavior, antiviral activity spectrum, and therapeutic potential for clinical use.Advances in Antiviral Drug DesignAntiviral agentsAnti-infective agentsAntiviral agents.Anti-infective agents.616.9616.9/25061/05616.91061De Clercq Erik66569MiAaPQMiAaPQMiAaPQBOOK9910784598503321Advances in antiviral drug design3755212UNINA